Ankylosing spondylitis does not go away. It is a lifelong inflammatory condition that affects the spine and sacroiliac joints, and fewer than 1% of patients who see a rheumatologist ever enter long-term remission where the disease fully quiets down. That said, many people reach a state of low disease activity where symptoms become manageable, especially with early treatment and consistent exercise.
Why It Doesn’t Burn Out on Its Own
There’s a longstanding idea that ankylosing spondylitis eventually “burns out,” meaning the inflammation simply stops after enough years. Research doesn’t support this. A study tracking patients over decades found that disease activity at follow-up was independent of how long someone had been diagnosed. Patients who started with high disease activity mostly stayed in that range (63% remained in their original severity group), and those with low activity also tended to stay put (77%). The disease doesn’t reliably fade with time.
About 90% of people with ankylosing spondylitis carry a genetic marker called HLA-B27, compared to less than 8% of the general population. This genetic component helps explain why the immune system continues to drive inflammation indefinitely. The underlying autoimmune process persists even when symptoms temporarily improve.
What Remission Actually Means
Doctors define remission in ankylosing spondylitis differently than you might expect. It doesn’t mean the disease is gone. It means inflammation has dropped below a specific threshold on standardized scoring systems. A score below 1.3 on the most commonly used disease activity scale qualifies as “inactive disease,” while a score between 1.3 and 2.1 indicates moderate activity. Remission typically requires ongoing treatment to maintain.
Achieving these low scores is realistic for many patients, particularly those who start biologic medications early. But stopping treatment usually leads to a return of symptoms. Remission in ankylosing spondylitis is something you sustain, not something you reach and walk away from.
Flares Are Part of the Pattern
Even with treatment, ankylosing spondylitis tends to cycle between calmer periods and flares. Research tracking patients week by week found roughly 71 flares per 100 person-weeks, most of them minor. Major flares, the kind that disrupt daily life, occurred at a rate of about 12 per 100 person-weeks and lasted an average of 2.4 weeks each.
Morning stiffness is one of the hallmark daily symptoms. It typically lasts at least 30 minutes and eases as you move through the day or with physical activity. This pattern of stiffness improving with movement (rather than rest) is one of the features that distinguishes inflammatory back pain from a mechanical injury.
How Treatment Slows the Disease
While no medication cures ankylosing spondylitis, biologic therapies that target the inflammatory process can significantly slow structural damage. TNF inhibitors, the most widely studied class, reduce the odds of new bone spurs forming in the spine by more than 50%. Patients who stayed on these medications for more than half of their total disease duration had an 80% lower chance of radiographic progression compared to untreated patients.
Timing matters enormously. Patients who waited more than 10 years before starting biologic therapy were 2.4 times more likely to see their spine worsen on imaging compared to those who started earlier. This is one of the strongest arguments for early diagnosis and treatment: the damage that accumulates before treatment begins is largely irreversible.
What Happens to the Spine Over Time
The fear many people have is spinal fusion, where vertebrae gradually lock together from new bone growth. This does happen, but not to everyone. In a study of 769 patients, complete spinal fusion occurred in about 28% of those who had the disease for 30 to 40 years, and in roughly 43% of those with 40 or more years of disease. That means more than half of patients did not develop complete fusion even after four decades. These numbers also reflect an era before modern biologic therapies were widely available, so current rates may be lower.
The Disease Can Affect More Than Your Spine
Ankylosing spondylitis isn’t limited to the back. About 24% of adults with the condition develop uveitis, a painful inflammation inside the eye that causes redness, blurred vision, and light sensitivity. This is the most common extra-spinal complication. The disease also shares pathways with inflammatory bowel conditions and, less commonly, psoriasis. These overlapping conditions don’t appear in every patient, but they’re worth being aware of because they may need separate treatment.
Exercise Has a Measurable Effect
Regular physical activity is one of the most effective tools for managing ankylosing spondylitis alongside medication. A large meta-analysis comparing different exercise types found that combining aerobic exercise with Pilates was the most effective approach for reducing both disease activity scores and spinal stiffness. Yoga, supervised stretching routines, and qigong also showed significant benefits over conventional care alone.
The benefits aren’t just about flexibility. Exercise directly lowers measurable disease activity, not just how you feel but how actively inflamed your body is. The analysis found non-linear dose-response relationships, meaning there are specific ranges of exercise volume that produce the best results rather than a simple “more is better” equation. Working with a physiotherapist who understands the condition can help you find that range.
Living With a Condition That Stays
Accepting that ankylosing spondylitis is permanent can be difficult, but the practical outlook is better than it was a generation ago. Early biologic treatment cuts structural damage by half or more. Consistent exercise reduces symptoms and preserves mobility. Most people will not end up with a fully fused spine. The disease stays, but for many patients, its impact shrinks considerably with the right combination of medication, movement, and monitoring over time.